Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the stock. HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS stock opened at $0.55 on Monday. The firm has a 50 day moving average of $0.54 and a 200-day moving average of $0.79. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $9.69. The firm has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter worth approximately $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter worth approximately $54,000. World Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals during the third quarter worth approximately $104,000. Deltec Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter worth approximately $107,000. Finally, XTX Topco Ltd raised its stake in shares of Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 206,614 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.